stockrow
Friday 6 November 2026
Export MBOT’s income statement to Excel — free account
Microbot Medical Inc.
MBOT Healthcare Medical Devices
- Revenue
- +1,047.6%
- EPS
- +20.0%
- Free cash flow
- −98.7%
Quarter to June 2026, against a year earlier
1.10
0.03
+2.80%
Follow MBOT
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 838.17 | 317.04 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (32.03) | (26.25) | |
P/B ratio |
— | — | 2.18 | 1.90 | |
Price to Tangible BV |
— | — | 2.19 | 1.90 | |
EV/Sales |
— | — | 475.01 | 159.71 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (6.02) | (3.74) | |
EV/FCF |
— | — | (5.96) | (3.68) | |
Quick Ratio |
27.34 | 22.97 | 21.50 | 17.42 | |
Current Ratio |
27.53 | 23.33 | 22.59 | 18.56 | |
Net Debt/EBITDA |
20.83 | 18.90 | 16.74 | 10.95 | |
Debt/Assets |
0.00% | 0.70% | 0.74% | 0.00% | |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
1.07 | 1.08 | 1.38 | 0.89 | |
Capex/Depreciation |
(1.30) | (2.50) | (9.00) | (9.47) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,231.43% | 772.20% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,884.76% | 1,528.63% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 211.43% | 179.67% | |
Graham Net Nets |
— | — | 0.45 | 0.52 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (10.79%) | (12.31%) | |
Free Cash Flow Yield |
— | — | (9.50%) | (13.69%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.08) | (0.08) | (0.08) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.08) | (0.08) | (0.08) | |
Cash per Share |
1.67 | 1.72 | 1.08 | 1.01 | |
Shareholders Equity per Share |
1.63 | 1.69 | 1.10 | 1.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.63 | 1.69 | 1.10 | 1.03 | |
Free Cash Flow |
(3.85) | (3.78) | (5.16) | (5.13) | |
Working Capital |
77.85 | 76.40 | 73.14 | 68.29 | |
Capital Expenditures |
(0.01) | (0.02) | (0.11) | (0.14) | |
Net Current Asset Value |
77.25 | 75.83 | 72.57 | 67.74 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 1.03 | 0.59 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.22 | 0.18 | |
Average Payables |
0.38 | 0.34 | 0.64 | 0.69 | |
Average Assets |
43.48 | 43.79 | 54.48 | 53.25 | |
Average Common Equity |
41.02 | 40.54 | 51.53 | 49.64 |
Columns are period end dates